2013
DOI: 10.1016/j.redar.2012.11.006
|View full text |Cite
|
Sign up to set email alerts
|

Descripción de los efectos hemodinámicos y respiratorios del tratamiento mediante hemoperfusión con polimixina B en pacientes con shock séptico de origen abdominal

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…Many studies have reported diverse benefits of PMX hemoperfusion in septic patients, including improved hemodynamics [24, 25, 5260], increased ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO 2 /FiO 2 ) [24, 54, 55, 57, 58, 60, 61], decreased 28-day mortality [24, 52, 53, 59], and decreased endotoxin levels [52, 53, 55, 58, 59, 6264]. In a multicenter study, Vincent et al [25] found that PMX hemoperfusion was safe and improved cardiac and renal function due to sepsis or septic shock; however, they could not demonstrate a reduction in mortality or in endotoxin levels from baseline to the end of treatment.…”
Section: Immunological Mechanisms Described For Polymyxin B-immobimentioning
confidence: 99%
“…Many studies have reported diverse benefits of PMX hemoperfusion in septic patients, including improved hemodynamics [24, 25, 5260], increased ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO 2 /FiO 2 ) [24, 54, 55, 57, 58, 60, 61], decreased 28-day mortality [24, 52, 53, 59], and decreased endotoxin levels [52, 53, 55, 58, 59, 6264]. In a multicenter study, Vincent et al [25] found that PMX hemoperfusion was safe and improved cardiac and renal function due to sepsis or septic shock; however, they could not demonstrate a reduction in mortality or in endotoxin levels from baseline to the end of treatment.…”
Section: Immunological Mechanisms Described For Polymyxin B-immobimentioning
confidence: 99%